[Prospect of novel therapies in immune-mediated neuropathies].
Rinsho Shinkeigaku
; 64(1): 1-7, 2024 Jan 20.
Article
de Ja
| MEDLINE
| ID: mdl-38072443
The efficacy of immunotherapies such as steroids, plasmapheresis, and intravenous immunoglobulin have been proven in various immune-mediated neuropathies. However, these treatments sometimes lack the efficacy in a part of patients with the immune-mediated neuropathies. In addition, anti-myelin associated glycoprotein (MAG) neuropathy is usually refractory to the treatments. Recently, novel therapies targeting a molecule which are associated with pathogenesis of immune-mediated diseases, have been developed. These molecularly targeted therapies are notable in immune-mediated neuropathies as novel drug candidates. In the present article, current treatments and future prospect of novel therapies in immune-mediated neuropathies will be reviewed.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Syndrome de Guillain-Barré
/
Polyradiculonévrite inflammatoire démyélinisante chronique
Limites:
Humans
Langue:
Ja
Journal:
Rinsho Shinkeigaku
Année:
2024
Type de document:
Article
Pays de publication:
Japon